ArticleACS omega2020
Dimerization of Doxorubicin Causes Its Precipitation.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- APTES-functionalized GdRSC advances · 2026Article
- Oleic Acid-Coated Zinc Ferrite Nanocubes: A Promising Nanocarrier for Neuroblastoma Therapy.ACS omega · 2026Article
- Synthesis of Folic Acid-Functionalized Hybrid Mesoporous Silica Nanoparticles and In Vitro Evaluation on MCF-7 Breast Cancer Cells.International journal of molecular sciences · 2026Article
- The Optimal Amount of PAMAM G3 Dendrimer in Polyurethane Matrices Makes Them a Promising Tool for Controlled Drug Release.Polymers · 2026Article
- Stable Cholesterol-Palmitic Acid Sterosomes as Smart Nanocarriers for pH-Sensitive Doxorubicin Delivery in Breast Cancer Therapy.Pharmaceutics · 2025Article
- Incorporation of doxorubicin into plant-derived nanovesicles: process monitoring and activity assessment.Drug delivery · 2025Article
- Nanoscale strategies: doxorubicin resistance challenges and enhancing cancer therapy with advanced nanotechnological approaches.Drug delivery and translational research · 2025Review
- Electrospun PMVEMA Nanofibers Developed as a Fast-Release Platform for Antineoplastic Drugs Tested in Glioblastoma Primary Cultures.Pharmaceutics · 2025Article
- Synthesis and Characterization of Polymer-Drug Conjugates by Strain-Promoted Azide-Alkyne Cycloaddition-Mediated Polymerization.Journal of applied polymer science · 2025Article
- Refining the adriamycin-induced focal segmental glomerulosclerosis mouse model to improve reproducibility and animal welfare.Animal models and experimental medicine · 2025Article
- Gemcitabine-Doxorubicin Combination Polymer-Drug Conjugate Prepared by SPAAC Click Chemistry: In Vitro Characterization.International journal of molecular sciences · 2025Article
- Characterization and in vitro anticancer study of PEGylated liposome dually loaded with ferulic acid and doxorubicin.Scientific reports · 2025Article
- Theoretical and Experimental Analyses of the Interfacial Mechanism of Dendrimer-Doxorubicin Complexes Formation.Molecular pharmaceutics · 2024Article
- The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells.Molecular therapy. Oncology · 2024Article
- Physicochemical characterization and potential cancer therapy applications of hydrogel beads loaded with doxorubicin and GaOOH nanoparticles.Scientific reports · 2024Article
- Dendrimer Platforms for Targeted Doxorubicin Delivery-Physicochemical Properties in Context of Biological Responses.International journal of molecular sciences · 2024Article
- Development of Aerosol Dry Powder Chemotherapeutic-Loaded Microparticles for the Treatment of Lung Cancer.AAPS PharmSciTech · 2024Article
- Recent Advances in Kaolinite Nanoclay as Drug Carrier for Bioapplications: A Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Delicate Hybrid Laponite-Cyclic Poly(ethylene glycol) Nanoparticles as a Potential Drug Delivery System.Pharmaceutics · 2023Article
- Anticancer Drug Doxorubicin Spontaneously Reacts with GTP and dGTP.Chemical research in toxicology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is commonly used in chemotherapy and biomedical research because of its potent anticancer activity. Although DOX is water soluble, it precipitates when interacting with buffers, such as phosphate-buffered saline, or with drugs such as 5-fluorouracil (5-FU) and heparin. This study reports that DOX precipitates in neutral buffers and 5-FU solution because of the formation of covalently bonded DOX dimers. Additionally, this study proposes a structure for the DOX dimer and a mechanism for dimerization on the basis of mass spectrometry in combination with an experiment to establish the reaction model. The DOX dimer/precipitate formation might be an important phenomenon, considering the frequent use of DOX in chemotherapy and biomedical research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.